BIND Biosciences announced today the presentation of its Medicinal Nanoengineering™ platform at the ACS National Meeting, including results from preclinical studies on its lead nanomedicine drug , BIND-014, scheduled to enter clinical trials later this year. BIND-014 is a targeted, polymeric nanoparticle containing the cytotoxic agent, docetaxel, which is approved in major cancer indications, including breast, prostate and lung. In animal models of human cancers, BIND-014 was shown to deliver up to 20 times more docetaxel to the tumor site than an equivalent dose of Taxotere®. The increased accumulation of docetaxel at the site of disease was shown in preclinical models to lead to marked improvements in antitumor activity and tolerability.
“We have shown in preclinical studies with BIND-014 and other drug candidates that our platform can produce more effective, less toxic drugs by targeting our drug compounds precisely to the site of disease.”
At the ACS National Meeting, Dr. Jeff Hrkach, Senior Vice President of Pharmaceutical Sciences at BIND, will present the latest preclinical data showing the efficacy of BIND-014, as well as presenting results of preclinical studies using the company's Medicinal Nanoengineering proprietary technology for BIND's drug candidates in oncology, inflammatory diseases and cardiovascular disorders. The presentation will be part of a three-day symposium on the advancement of nanomedicine at the ACS National Meeting, taking place in Boston from August 22 through August 26. Dr. Hrkach's presentation, "High-precision therapeutics through Medicinal Nanoengineering," will be Tuesday, August 24 at 3:55 PM in The Westin Boston Waterfront, Grand Ballroom C.
In addition, both of BIND's scientific co-founders, Dr. Robert Langer, MIT David H. Koch Institute Professor, and Dr. Omid Farokhzad, Harvard Medical School Associate Professor, have been invited to present at the nanomedicine symposium at the ACS.
- Dr. Langer delivered the opening keynote address for the nanomedicine symposium, "Nanotechnology and its potential in medicine," on Sunday, August 22.
- Dr. Farokhzad will make a presentation, "Medical nanoengineering: Multifunctional polymeric nanoparticles for medical applications," on Monday, August 23, with the results and drug discovery translation of his pioneering academic research in nanomedicine technology.
"As our recent data show, BIND's Medicinal Nanoengineering approach has the potential to significantly improve upon the traditional drug development process and produce best-in-class new drugs," said Jeff Hrkach, Senior VP at BIND. "We have shown in preclinical studies with BIND-014 and other drug candidates that our platform can produce more effective, less toxic drugs by targeting our drug compounds precisely to the site of disease."